# Adaptate Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/adaptate-biotherapeutics

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.adaptate.com
- Total disclosed funding: $18M
- Latest round: Series A (Apr 19, 2021)
- Investors on record: 2

## About

Based in London, UK, and founded in 2019 by Professor Adrian Hayday, Adaptate Biotherapeutics Ltd trading as Adaptate, is a biotechnology company that develops therapeutic antibodies that modulate gamma delta T-cells spun out of GammaDelta Therapeutics and led by its CEO Natalie Mount. In January 2022, Takeda Pharmaceutical agreed to acquire Adaptate Biotherapeutics Ltd.

Adaptate Biotherapeutics Ltd is focused on developing therapeutic antibodies to modulate the activity of gamma delta T cells located throughout the blood and tissues of the body. T cells recognize malignant cells by a pattern of markers expressed by dysregulated, transformed cells rather than any specific antigen. 

Following the acquisition, Adaptate Biotherapeutics Ltd is intended to further accelerate the development of T cell-based therapies.

## Funding rounds

- Series A, Apr 19, 2021, $18M — Abingworth, Takeda Ventures

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series A